Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-12T18:45:23.594Z Has data issue: false hasContentIssue false
  • English
  • Français

Impulse-Control Disorders in Parkinson's Disease

Published online by Cambridge University Press:  07 November 2014

Joseph M. Ferrara and
Mark Stacy
Get accessRights & Permissions [Opens in a new window]

Abstract

Parkinson's disease is a neurodegenerative disorder characterized by bradykinesia, rigidity, postural instability, and resting tremor. Increasingly, Parkinson's disease has been associated with a broad spectrum of non-motor symptoms, such as olfactory loss, sleep disorders, autonomic dysfunction, cognitive impairment, psychosis, depression, anxiety, and apathy. In addition, a minority of Parkinson's disease patients develop compulsive behaviors while receiving dopamine-replacement therapy, including medication hoarding, pathological gambling, binge eating, hyperlibidinous behavior, compulsive shopping, and punding. These behaviors may result in psychosocial impairment for patients and therapeutic challenges for clinicians. This article reviews the anatomic substrates, behavioral spectrum, associated factors, and potential treatments for dopamine-replacement therapy-related compulsions in Parkinson's disease.

Information

Type
Review Articles
Information
CNS Spectrums , Volume 13 , Issue 8 , August 2008, pp. 690 - 698
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

REFERENCES

1.DeLong, MR, Wichmann, T. Circuits and circuit disorders of the basal ganglia. Arch Neurol. 2007;64:20–24.CrossRefGoogle ScholarPubMed
2.Alexander, GE, DeLong, MR, Strick, PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357–381.CrossRefGoogle ScholarPubMed
3.Mink, JW. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol. 1996:50:381–425.Google Scholar
4.Horvitz, JC. Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience. 2000;96:651–656.CrossRefGoogle ScholarPubMed
5.Evans, AH, Pavese, N, Lawrence, AD, et al.Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. 2006;59:852–858.Google Scholar
6.Volkow, ND, Fowler, JS, Wang, GJ, Swanson, JM, Telang, F. Dopamine in drug abuse and addiction-results of imaging studies and treatment implications. Arch Neurol. 2007;64:1575–1579.CrossRefGoogle ScholarPubMed
7.Levy, R, Czernecki, V. Apathy and the basal ganglia. J Neurol. 2006;253(suppl 7):VII54–VII61.CrossRefGoogle ScholarPubMed
8.Ishihara, L, Brayne, C. What is the evidence for a premorbid parkinsonian personality: a systematic review. Mov Disord. 2006;21:1066–1072.CrossRefGoogle ScholarPubMed
9.Benedetti, MD, Bower, JH, Maraganore, DM, et al.Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology. 2000;55:1350–1358.CrossRefGoogle ScholarPubMed
10.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. text rev. Washington, DC: American Psychiatric Association: 2000.Google Scholar
11.Giovannoni, G, O'Sullivan, JD, Turner, K, Manson, AJ, Lees, AJ. Hedonistic homeo-static dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68:423–428.CrossRefGoogle Scholar
12.McElroy, SL, Keck, PE Jr, Pope, HG Jr, Smith, JM, Strakowski, SM. Compulsive buying: a report of 20 cases. J Clin Psychiatry. 1994;55:242–248.Google Scholar
13.Voon, V, Hassan, K, Zurowski, M, et al.Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology. 2006;67:1254–1257.Google Scholar
14.Courty, E, Durif, F, Zenut, M, Courty, P, Lavarenne, J. Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease. Clin Neuropharmacol. 1997;20:140–147.Google Scholar
15.Uitti, RJ, Tanner, CM, Rajput, AH, Goetz, CG, Klawans, HL, Thiessen, B. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 1989;12:375–383.Google Scholar
16.Quinn, NP, Toone, B, Lang, AE, Marsden, CD, Parkes, JD. Dopa dose-dependent sexual deviation. Br J Psychiatry. 1983;142:296–298.CrossRefGoogle ScholarPubMed
17.Berger, CH, Mehrhoff, FW, Beier, KM, Meinck, MH. Sexual delinquency and Parkinson's disease. Nervenarzt. 2003;74:370–375.Google Scholar
18.Riley, DE. Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline. Clin Neuropharmacol. 2002;25:234–237.Google Scholar
19.Jimenez-Jimenez, FJ, Sayed, Y, Garcia-Soldevilla, MA, Barcenilla, B. Possible zoophilia associated with dopaminergic therapy in Parkinson disease. Ann Pharmacother. 2002;36:1178–1179.CrossRefGoogle ScholarPubMed
20.Kanovsky, RM. Bares, M, Pohanka, M, Rektor, I. Penile erections and hypersexuality induced by pergolide treatment in advanced, fluctuating Parkinson's disease. J Neurol. 2002;249:112–114.CrossRefGoogle ScholarPubMed
21.Voon, V, Hassan, K, Zurowski, M, et al.Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology. 2006;66:1750–1752.CrossRefGoogle ScholarPubMed
22.Grosset, KA, Macphee, G, Pal, G, et al.Problematic gambling on dopamine agonists: Not such a rarity. Mov Disord. 2006;21:2206–2208.CrossRefGoogle ScholarPubMed
23.Molina, JA, Sainz-Artiga, MJ, Fraile, A, et al.Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord. 2000;15:869–872.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
24.Rylander, G. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr Neurol Neurochi. 1972;75:203–212.Google ScholarPubMed
25.Andén, NE, Carlsson, A, Kerstell, J, et al.Oral L-dopa treatment of parkinsonism. Acta Med Scand. 1970;187:247–255.CrossRefGoogle ScholarPubMed
26.Friedman, JH. Punding on levodopa. Biol Psychiatry. 1994;36:350–351.CrossRefGoogle ScholarPubMed
27.Fernande, HH, Friedman, JH. Punding on L-dopa. Mov Disord. 1999;14:836–838.Google Scholar
28.Evans, AH, Katzenschlager, R, Paviour, D, et al.Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome. Mov Disord. 2004;19:397–405.CrossRefGoogle Scholar
29.Kurlan, R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord. 2004;19:433–437.CrossRefGoogle ScholarPubMed
30.Voon, V. Repetition, repetition, and repetition: compulsive and punding behaviors in Parkinson's disease. Mov Disord. 2004;19:367–370.Google Scholar
31.Kumar, S. Punding in Parkinson's disease related to high-dose levodopa therapy. Neurol India. 2005;53:362.Google Scholar
32.Fasano, A, Elia, AE, Soleti, F, Guidubaldi, A, Bentivoglio, AR. Punding and computer addiction in Parkinson's disease. Mov Disord. 2006;21:1217–1218.CrossRefGoogle ScholarPubMed
33.Silveira-Moriyama, L, Evans, AH, Katzenschlager, R, Lees, AJ. Punding and dyskinesias. Mov Disord. 2006;21:2214–1217.CrossRefGoogle ScholarPubMed
34.Micheli, F, Fernandez Pardal, M, Giannaula, R, Fahn, S. What Is it? Case 3, 1991: moaning in a man with parkinsonian signs. Mov Disord. 1991;6:376–378.CrossRefGoogle Scholar
35.Miwa, H, Kondo, T. Increased writing activity in Parkinson's disease: a punding-like behavior? Parkinsonism Relat Disord. 2005;11:323–325.CrossRefGoogle ScholarPubMed
36.Miyasaki, JM, AI Hassan, K, Lang, AE, Voon, V. Punding prevalence in Parkinson's disease. Mov Disord. 2007;22:1179–1181.Google Scholar
37.Cools, R, Barker, RA, Sahakian, BJ, Robbins, TW. L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia. 2003;41:1431–1441.CrossRefGoogle ScholarPubMed
38.Ondo, WG, Lai, D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord. 2008;14:28–32.Google Scholar
39.Pezzella, FR, Di Rezze, S, Chianese, M, et al.Hedonistic homeostatic dysregulation in Parkinson's disease: a short screening questionnaire. Neurol Sci. 2003;24:205–206.CrossRefGoogle ScholarPubMed
40.Lesieur, HR, Blume, SB. The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry. 1987;144:1184–1188.Google Scholar
41.Weintraub, D, Siderowf, AD, Potenza, MN, et al.Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63:969–973.Google Scholar
42.Pontone, G. Williams, JR, Bassett, SS, Marsh, L. Clinical features associated with impulse control disorders In Parkinson disease. Neurology. 2006;67:1258–1261.CrossRefGoogle ScholarPubMed
43.Weintraub, D, Koester, J, Potenza, MN, et al. Dopaminergic therapy and Impulse control disorders in Parkinson's disease: a cross-sectional study of over 3,000 patients. Papaer presented at: The Movement Disorder Society's 12th International Congress of Parkinson's Disease and Movement Disorders. June 22-26, 2008; Chicago, Ill.Google Scholar
44.Pezzella, FR, Colosimo, C, Vanacore, N, et al.Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord. 2005;20:77–81.Google Scholar
45.Steiner, I, Wirguin, I. Levodopa addiction in non-parkinsonian patients. Neurology. 2003;61:1451.CrossRefGoogle ScholarPubMed
46.Lily, O, AI-Din, A. Case study: cerebrovascular parkinsonism with levodopa addiction. J Neurol Neurosurg Psychiatry. 2004;75:1365–1366.Google Scholar
47.Tippmann-Peikert, M, Park, JG, Boeve, BF. Shepard, JW, Silber, MH. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology. 2007;68:301–303.CrossRefGoogle ScholarPubMed
48.Evans, AE, Butzkueven, H. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov Disord. 2007;22:590–591.Google Scholar
49.Quickfall, J, Suchowersky, O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord. 2007;13:535–536.CrossRefGoogle ScholarPubMed
50.Driver-Dunckley, E, Samanta, J, Stacy, M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology. 2003;61:422–423.CrossRefGoogle ScholarPubMed
51.Dodd, ML, Klos, KJ, Bower, JH, Geda, YE, Josephs, KA, Ahlskog, JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62:1377–1381.Google Scholar
52.Avanzi, M, Uber, E, Bonfà, F. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease: Neurol Sci. 2004;25:98–101.CrossRefGoogle ScholarPubMed
53.Drapier, D, Drapier, S, Sauleau, P, et al.Pathological gambling secondary to dopaminergic therapy in Parkinson's disease. Psychiatry Res. 2006;144:241–244.CrossRefGoogle ScholarPubMed
54.Ardouin, C, Voon, V, Worbe, Y, et al.Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord. 2006;21:1941–1946.Google Scholar
55.Klos, KJ, Bower, JH, Josephs, KA, Matsumoto, JY, Ahlskog, JEPathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord. 2005;11:381–386.Google Scholar
56.Lawrence, AD, Evans, AH, Lees, AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol. 2003;2:595–604.Google Scholar
57.Avanzi, M, Baratti, M, Cabrini, S, Uber, E, Brighetti, G, Bonfà, F. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord. 2006;21:2068–2072.Google Scholar
58.Lu, C, Bharmal, A, Suchowersky, O. Gambling and Parkinson disease. Arch Neurol. 2006;63:298.Google Scholar
59.Voon, V, Thomsen, T, Miyasaki, JM, et al.Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol. 2007;64:212–216.CrossRefGoogle ScholarPubMed
60.Nirenberg, MJ, Waters, C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord. 2006;21:524–529.Google Scholar
61.Harvey, NS. Serial cognitive profiles in levodopa-induced hypersexuality. Br J Psychiatry. 1988;153:833–836.Google Scholar
62.Evans, AH, Lawrence, AD, Potts, J, Appel, S, Lees, AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology. 2005;65:1570–1574.Google Scholar
63.Voon, V, Schoerling, A, Wenzel, S, Trenkwalder, C. Prevalence and factors associated with dopaminergic-medication induced impulse control behaviors in restless legs syndrome. Mov Disord. 2008;23(suppl 1):s370.Google Scholar
64.Borek, LL, Friedman, JH. Levodopa addiction in idiopathic Parkinson disease. Neurology. 2005;65:1508.CrossRefGoogle ScholarPubMed
65.Mamikonyan, E, Siderowf, AD, Duda, JE, et al.Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord. 2008;23:75–80.CrossRefGoogle ScholarPubMed
66.Gschwandtner, U, Aston, J. Renaud, S, Fuhr, P. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol. 2001;24:170–172.Google Scholar
67.Ivanco, LS, Bohnen, NI. Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study. Am J Ther. 2005;12:467–468.Google Scholar
68.Witjas, T, Baunez, C, Henry, JM, et al.Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord. 2005;20:1052–1055.Google Scholar
69.Bandini, F, Primavera, A, Pizzorno, M, Cocito, L. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord. 2007;13:369–371.Google Scholar
70.Houeto, JL. Mesnage, V, Mallet, L, et al.Behavioural disorders. Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry. 2002;72:701–717.CrossRefGoogle ScholarPubMed
71.Romito, LM, Raja, M, Daniele, A, et al.Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord. 2002;17:1371–1374.Google Scholar
72.Mendez, MF, O'Connor, SM, Lim, GT. Hypersexuality after right pallidotomy for Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2004;16:37–40.CrossRefGoogle ScholarPubMed
73.Roane, DM, Yu, M, Feinberg, TE, Rogers, JD. Hypersexuality after pallidal surgery in Parkinson disease. Neuropsychiatry Neuropsychol Behav Neurol. 2002;15:247–251.Google ScholarPubMed
74.Smeding, HM, Goudriaan, AE, Foncke, EM, Schuurman, PR, Speelman, JD, Schmand, B. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007;78:517–519.Google Scholar
75.Morgan, JC, diDonato, CJ, Iyer, SS, Jenkins, PD, Smith, JR, Sethi, KD. Self-stimulatory behavior associated with deep brain stimulation in Parkinson's disease. Mov Disord. 2006;21:283–285.Google Scholar
76.Miwa, H, Morita, S, Nakanishi, I, Kondo, T. Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease. Parkinsonism Relat Disord. 2004;10:177–180.Google Scholar